Treating hallucinations in Parkinson’s disease

References

• Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson’s disease: report of an NINDS, NIMH work group. Mov Disord. 2007;22(8):1061–1068.
   PubMed Web of Science ®Google Scholar
• Ebersbach G, Ip CW, Klebe S, et al. Management of delirium in Parkinson’s disease. J Neural Transm. 2019. DOI:https://doi.org/10.1007/s00702-019-01980-7.
   Google Scholar
• Hely MA, Reid WGJ, Adena MA, et al. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23(6):837–844.
   PubMed Web of Science ®Google Scholar
• Fénelon G, Mahieux F, Huon R, et al. Hallucinations in Parkinson’s Parkinson’s disease: prevalence, phenomenology and risk factors. Brain. 2000;123(4):733–745.
   PubMed Web of Science ®Google Scholar
• Llebaria G, Pagonabarraga J, Martínez-Corral M, et al. Neuropsychological correlates of mild to severe hallucinations in Parkinson’s disease. Mov Disord. 2010;25(16):2785–2791.
   PubMed Web of Science ®Google Scholar
• Ffytche DH, Creese B, Politis M, et al. The psychosis spectrum in Parkinson disease. Nat Rev Neurol. 2017;13(2):81–95.
   PubMed Web of Science ®Google Scholar
• O’Brien J, Taylor JP, Ballard C, et al. Visual hallucinations in neurological and ophthalmological disease: pathophysiology and management. J Neurol Neurosurg Psychiatry. 2020;91(5):512–519.
   PubMed Web of Science ®Google Scholar
• Forsaa EB, Larsen JP, Wentzel-Larsen T, et al. What predicts mortality in Parkinson disease?: a prospective population-based long-term study. Neurology. 2010;75(14):1270–1276.
   PubMed Web of Science ®Google Scholar
• Fénelon G, Alves G. Epidemiology of psychosis in Parkinson’s disease. J Neurol Sci. 2010;289(1–2):12–17.
   PubMed Web of Science ®Google Scholar
• Liew TM. Neuropsychiatric symptoms in cognitively normal older persons, and the association with Alzheimer’s and non-Alzheimer’s dementia. Alzheimers Res Ther. 2020;12(1):35.
   PubMed Web of Science ®Google Scholar
• Frei K, Truong DD. Hallucinations and the spectrum of psychosis in Parkinson’s disease. J Neurol Sci. 2017;374:56–62.
   PubMed Web of Science ®Google Scholar
• Lenka A, Pagonabarraga J, Pal PK, et al. Minor hallucinations in Parkinson disease: a subtle symptom with major clinical implications. Neurology. 2019;93(6):259–266.
   PubMed Web of Science ®Google Scholar
• Diederich NJ, Fénelon G, Stebbins G, et al. Hallucinations in Parkinson disease. Nat Rev Neurol. 2009;5(6):331–342.
   PubMed Web of Science ®Google Scholar
• Pagonabarraga J, Martinez-Horta S, Fernández de Bobadilla R. Minor hallucinations occur in drug-naive Parkinson’s disease patients, even from the premotor phase. Mov Disord. 2016;31(1):45–52.
   PubMed Web of Science ®Google Scholar
• Inzelberg R, Kipervasser S, Korczyn AD. Auditory hallucinations in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1998;64(4):533–535.
   PubMed Web of Science ®Google Scholar
• Singh S, Schwankhaus J. Olfactory disturbance in Parkinson disease. Arch Neurol. 2009;66(805):805–806. author reply.
   PubMedGoogle Scholar
• Powell A, Ireland C, Lewis SJG. Visual hallucinations and the role of medications in Parkinson’s disease: triggers, pathophysiology, and management. J Neuropsychiatry Clin Neurosci. 2020;32(4):334-343.
   PubMed Web of Science ®Google Scholar
• Gibson G, Mottram PG, Burn DJ, et al. Frequency, prevalence, incidence and risk factors associated with visual hallucinations in a sample of patients with Parkinson’s disease: a longitudinal 4-year study. Int J Geriatr Psychiatry. 2013;28(6):626–631.
   PubMed Web of Science ®Google Scholar
• Zhu J, Shen B, Lu L, et al. Prevalence and risk factors for visual hallucinations in Chinese patients with Parkinson’s disease. J Neurol Sci. 2017;372:471–476.
   PubMed Web of Science ®Google Scholar
• Sinforiani E, Zangaglia R, Manni R, et al. REM sleep behavior disorder, hallucinations, and cognitive impairment in Parkinson’s disease. Mov Disord. 2006;21:462–466.
   PubMed Web of Science ®Google Scholar
• Goetz CG, Ouyang B, Negron A, et al. Hallucinations and sleep disorders in PD: ten-year prospective longitudinal study. Neurology. 2010;75(20):1773–1779.
   PubMed Web of Science ®Google Scholar
• Ffytche DH, Pereira JB, Ballard C, et al. Risk factors for early psychosis in PD: insights from the Parkinson’s progression markers initiative. J Neurol Neurosurg Psychiatry. 2017;88(4):325–331.
   PubMed Web of Science ®Google Scholar
• Uc EY, McDermott MP, Marder KS, et al. Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. Neurology. 2009;73(18):1469–1477.
   PubMed Web of Science ®Google Scholar
• Hepp DH, Vergoossen DLE, Huisman E, et al. Distribution and load of amyloid-β pathology in parkinson disease and dementia with lewy bodies. J Neuropathol Exp Neurol. 2016;75(10):936–945.
   PubMed Web of Science ®Google Scholar
• Jacobson SA, Morshed T, Dugger BN, et al. Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations. Parkinsonism Relat Disord. 2014;20(9):1009–1014.
   PubMed Web of Science ®Google Scholar
• Oeda T, Umemura A, Mori Y, et al. Impact of glucocerebrosidase mutations on motor and nonmotor complications in Parkinson’s disease. Neurobiol Aging. 2015;36:3306–3313.
   PubMed Web of Science ®Google Scholar
• Forsaa EB, Larsen JP, Wentzel-Larsen T, et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol. 2010;67(8):996–1001.
   PubMedGoogle Scholar
• Papapetropoulos S, Argyriou AA, Ellul J. Factors associated with drug-induced visual hallucinations in Parkinson’s disease. J Neurol. 2005;252(10):1223–1228.
   PubMed Web of Science ®Google Scholar
• Merims D, Shabtai H, Korczyn AD, et al. Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson’s disease. J Neural Transm (Vienna). 2004;111(10–11):1447–1453.
   PubMed Web of Science ®Google Scholar
• Aarsland D, Larsen JP, Cummins JL, et al. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol. 1999;56(5):595–601.
   PubMedGoogle Scholar
• Goetz CG, Pappert EJ, Blasucci LM, et al. Intravenous levodopa in hallucinating Parkinson’s disease patients: high-dose challenge does not precipitate hallucinations. Neurology. 1998;50(2):515–517.
   PubMed Web of Science ®Google Scholar
• Powell A, Muller AJ, O’Callaghan C, et al. Dopamine and functional connectivity in patients with Parkinson’s disease and visual hallucinations. Mov Disord. 2020;35(4):704–705.
   PubMed Web of Science ®Google Scholar
• Dave S, Weintraub D, Aarsland D, et al. Drug and disease effects in Parkinson’s psychosis: revisiting the role of dopamine. Mov Disord Clin Pract. 2020;7(1):32–36.
   PubMed Web of Science ®Google Scholar
• Russo M, Carrarini C, Dono F, et al. The pharmacology of visual hallucinations in synucleinopathies. Front Pharmacol. 2019;10:1379.
   PubMed Web of Science ®Google Scholar
• Clegg A, Young JB. Which medications to avoid in people at risk of delirium: a systematic review. Age Ageing. 2011;40(1):23–29.
   PubMed Web of Science ®Google Scholar
• Monastero R, Camarda C, Pipia C, et al. Visual hallucinations and agitation in Alzheimer’s disease due to memantine: report of three cases. J Neurol Neurosurg Psychiatry. 2007;78(5):546.
   PubMed Web of Science ®Google Scholar
• Krystal JH, Perry EB, Gueorguieva R, et al. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry. 2005;62(9):985–994.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Parkinson’s disease psychosis as a serotonin-dopamine imbalance syndrome. CNS Spectr. 2016;21(5):355–359.
   PubMed Web of Science ®Google Scholar
• Renouf S, Ffytche D, Pinto R, et al. Visual hallucinations in dementia and Parkinson’s disease: a qualitative exploration of patient and caregiver experiences. Int J Geriatr Psychiatry. 2018;33:1327–1334.
   PubMed Web of Science ®Google Scholar
• Mosimann UP, Mather G, Wesnes KA, et al. Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology. 2004;63:2091–2096.
   PubMed Web of Science ®Google Scholar
• Hong SB, Ahn J, Yoo D, et al. Contrast sensitivity impairment in drug-naïve Parkinson’s disease patients associates with early cognitive decline. Neurol Sci. 2020;41(7):1837-1842.
   Web of Science ®Google Scholar
• Schott JM. The neurology of ageing: what is normal? Pract Neurol. 2017;17:172–182.
   PubMedGoogle Scholar
• Buchman AS, Yu L, Wilson RS, et al. Progressive parkinsonism in older adults is related to the burden of mixed brain pathologies. Neurology. 2019;92:e1821–e1830.
   PubMed Web of Science ®Google Scholar
• Halliday GM, McCann H. The progression of pathology in Parkinson’s disease. Ann N Y Acad Sci. 2010;1184:188–195.
   PubMed Web of Science ®Google Scholar
• Noyce AJ, Bestwick JP, Silveira-Moriyama L, et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol. 2012;72:893–901.
   PubMed Web of Science ®Google Scholar
• Mosimann UP, Rowan EN, Partington CE, et al. Characteristics of visual hallucinations in Parkinson disease dementia and dementia with lewy bodies. Am J Geriatr Psychiatry. 2006;14:153–160.
   PubMed Web of Science ®Google Scholar
• Hesdorffer DC. Comorbidity between neurological illness and psychiatric disorders. CNS Spectr. 2016;21:230–238.
   PubMed Web of Science ®Google Scholar
• Durcan R, Wiblin L, Lawson RA, et al. Prevalence and duration of non-motor symptoms in prodromal Parkinson’s disease. Eur J Neurol. 2019;26:979–985.
   PubMed Web of Science ®Google Scholar
• Tampi RR, Young J, Hoq R, et al. Psychotic disorders in late life: a narrative review. Ther Adv Psychopharmacol. 2019;9:2045125319882798.
   Web of Science ®Google Scholar
• Goetz CG, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the unified Parkinson’s disease rating scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Disord. 2007;22:41–47.
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Martinez-Martin P, Brown RG, et al. The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study. Mov Disord. 2007;22:1901–1911.
   PubMed Web of Science ®Google Scholar
• Voss T, Bahr D, Cummings J, et al. Performance of a shortened scale for assessment of positive symptoms for Parkinson’s disease psychosis. Parkinsonism Relat Disord. 2013;19:295–299.
   PubMed Web of Science ®Google Scholar
• Visser M, Verbaan D, van Rooden SM, et al. Assessment of psychiatric complications in Parkinson’s disease: the SCOPA-PC. Mov Disord. 2007;22:2221–2228.
   PubMed Web of Science ®Google Scholar
• Shine JM, Mills JMZ, Qiu J, et al. Validation of the psychosis and hallucinations questionnaire in non-demented patients with Parkinson’s disease. Mov Disord Clin Pract. 2015;2:175–181.
   PubMed Web of Science ®Google Scholar
• Muller AJ, Mills JMZ, O’Callaghan C, et al. Informant- and self-appraisals on the psychosis and hallucinations questionnaire (PsycH-Q) enhances detection of visual hallucinations in Parkinson’s disease. Mov Disord Clin Pract. 2018;5:607–613.
   PubMedGoogle Scholar
• Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review. Mov Disord. 2019;34:180–198.
   PubMed Web of Science ®Google Scholar
• Lizarraga KJ, Fox SH, Strafella AP, et al. Hallucinations, delusions and impulse control disorders in Parkinson disease. Clin Geriatr Med. 2020;36:105–118.
   PubMed Web of Science ®Google Scholar
• Nowacka B, Lubinski W, Honczarenko K, et al. Ophthalmological features of Parkinson disease. Med Sci Monit. 2014;20:2243–2249.
   PubMed Web of Science ®Google Scholar
• Marques A, Beze S, Pereira B, et al. Visual hallucinations and illusions in Parkinson’s disease: the role of ocular pathology. J Neurol. 2020;267(10):2829-2841.
   PubMed Web of Science ®Google Scholar
• Rebol J, Kravos M, Ložar M. Successful hearing improvement with direct acoustic stimulation in a patient with schizophrenia. J Laryngol Otol. 2018;132:946–948.
   PubMed Web of Science ®Google Scholar
• Hshieh TT, Yang T, Gartaganis SL, et al. Hospital elder life program: systematic review and meta-analysis of effectiveness. Am J Geriatr Psychiatry. 2018;26:1015–1033.
   PubMed Web of Science ®Google Scholar
• Thomas N, Hayward M, Peters E, et al. Psychological therapies for auditory hallucinations (voices): current status and key directions for future research. Schizophr Bull. 2014;40(4):S202–212.
   PubMedGoogle Scholar
• Friedman JH. Pharmacological interventions for psychosis in Parkinson’s disease patients. Expert Opin Pharmacother. 2018;19:499–505.
   PubMed Web of Science ®Google Scholar
• Minton L, Perepezko K, Pontone G. Psychosis: a mind guide to Parkinson’s disease. Miami: Parkinson’s Foundation; 2018.
   Google Scholar
• Parkinson’s Australia. Information sheets [Internet]. [cited 2020 Jul 12]. Available from: https://www.parkinsons.org.au/information-sheets
   Google Scholar
• Shake it Up Australia Foundation. Ask the MD: Parkinson’s disease and psychosis [Internet]. [cited 2020 Jul 12]. Available from: https://shakeitup.org.au/ask-md-parkinsons-disease-psychosis/.
   Google Scholar
• Parkinson’s Foundation. Hallucinations/delusions [Internet]. [cited 2020 Jul 12]. Available from: https://www.parkinson.org/Understanding-Parkinsons/Symptoms/Non-Movement-Symptoms/Hallucinations-Delusions.
   Google Scholar
• Vandepitte S, Van Den Noortgate N, Putman K, et al. Effectiveness of respite care in supporting informal caregivers of persons with dementia: a systematic review. Int J Geriatr Psychiatry. 2016;31:1277–1288.
   PubMed Web of Science ®Google Scholar
• By the American Geriatrics Society. Beers criteria update expert panel. American geriatrics society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63:2227–2246.
   PubMed Web of Science ®Google Scholar
• King R, Rabino S ACB calculator [Internet]. 2020 [cited 2020 May 7]. Available from: http://www.acbcalc.com/pages/about.
   Google Scholar
• Lenka A, Herath P, Christopher R, et al. Psychosis in Parkinson’s disease: from the soft signs to the hard science. J Neurol Sci. 2017;379:169–176.
   PubMed Web of Science ®Google Scholar
• Burn D, Emre M, McKeith I, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson’s disease. Mov Disord. 2006;21:1899–1907.
   PubMed Web of Science ®Google Scholar
• Szeto JYY, Lewis SJG. Current treatment options for Alzheimer’s disease and Parkinson’s disease dementia. Curr Neuropharmacol. 2016;14:326–338.
   PubMed Web of Science ®Google Scholar
• Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med. 2004;351:2509–2518.
   PubMed Web of Science ®Google Scholar
• Emre M, Poewe W, De Deyn PP, et al. Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study. Clin Neuropharmacol. 2014;37:9–16.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Exelon patch (rivastigmine) label - FDA [Internet]; 2010. Available from: https://www.accessdata.fda.gov›drugsatfda_docs›label.Accessed: 22/11/2020.
   Google Scholar
• Greenspoon J, Herrmann N, Adam DN. Transdermal rivastigmine: management of cutaneous adverse events and review of the literature. CNS Drugs. 2011;25:575–583.
   PubMed Web of Science ®Google Scholar
• Dubois B, Tolosa E, Katzenschlager R, et al. Donepezil in Parkinson’s disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord. 2012;27:1230–1238.
   PubMed Web of Science ®Google Scholar
• Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson’s disease with dementia. Int J Geriatr Psychiatry. 2003;18:937–941.
   PubMed Web of Science ®Google Scholar
• Ballard CG, Court JA, Piggott M, et al. Disturbances of consciousness in dementia with Lewy bodies associated with alteration in nicotinic receptor binding in the temporal cortex. Conscious Cogn. 2002;11:461–474.
   PubMed Web of Science ®Google Scholar
• Litvinenko IV, Odinak MM, Mogil’naya VI, et al. Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson’s disease (an open controlled trial). Neurosci Behav Physiol. 2008;38:937–945.
   PubMedGoogle Scholar
• Grace J, Amick MM, Friedman JH. A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease. J Neurol Neurosurg Psychiatry. 2009;80:18–23.
   PubMed Web of Science ®Google Scholar
• Huang Y, Alsabbagh MW. Comparative risk of cardiac arrhythmias associated with acetylcholinesterase inhibitors used in treatment of dementias - A narrative review. Pharmacol Res Perspect. 2020;8:e00622.
   PubMed Web of Science ®Google Scholar
• Rolinski M, Fox C, Maidment I, et al. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. Cochrane Database Syst Rev. 2012;CD:006504.
   Google Scholar
• US Food and Drug Administration. Aricept (donepezil hydrochloride) label - FDA [Internet]; 2012. Available from: https://www.accessdata.fda.gov›drugsatfda_docs›label.Access date 22/11/2020.
   Google Scholar
• US Food and Drug Administration. Razadyne label - FDA [Internet]; 2015. Available from: https://www.accessdata.fda.gov›drugsatfda_docs›label.Access date 22/11/2020.
   Google Scholar
• Ueda K, Katayama S, Arai T, et al. Efficacy, safety, and tolerability of switching from oral cholinesterase inhibitors to rivastigmine transdermal patch with 1-step titration in patients with mild to moderate Alzheimer’s disease: a 24-week, open-label, multicenter study in Japan. Dement Geriatr Cogn Dis Extra. 2019;9:302–318.
   PubMed Web of Science ®Google Scholar
• Reeve E, Farrell B, Thompson W, et al. Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary. Med J Aust. 2019;210:174–179.
   PubMed Web of Science ®Google Scholar
• Minett TSC, Thomas A, Wilkinson LM, et al. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson’s disease with dementia. Int J Geriatr Psychiatry. 2003;18:988–993.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes. CNS Spectr. 2017;22:375–384.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Mechanism of action of pimavanserin in Parkinson’s disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors. CNS Spectr. 2016;21:271–275.
   PubMed Web of Science ®Google Scholar
• Ward KM, Citrome L. Antipsychotic-Related Movement Disorders: drug-Induced Parkinsonism vs. Tardive Dyskinesia-Key Differences in Pathophysiology and Clinical Management. Neurol Ther. 2018;7:233–248.
   PubMed Web of Science ®Google Scholar
• Citrome L, McEvoy JP, Saklad SR. Guide to the management of clozapine-related tolerability and safety concerns. Clin Schizophr Relat Psychoses. 2016;10:163–177.
   PubMedGoogle Scholar
• Fox SH. Non-dopaminergic treatments for motor control in Parkinson’s disease. Drugs. 2013;73:1405–1415.
   PubMed Web of Science ®Google Scholar
• Moreno GM, Gandhi R, Lessig SL, et al. Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine. Neurology. 2018;91:797–799.
   PubMed Web of Science ®Google Scholar
• Department of Health and Human Services, US Government. Food and drug administration (FDA) public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances [Internet]; 2005. Available from: www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm053171.htm.Access date: 22/11/2020.
   Google Scholar
• Ralph SJ, Espinet AJ. Increased all-cause mortality by antipsychotic drugs: updated review and meta-analysis in dementia and general mental health care. J Alzheimers Dis Rep. 2018;2:1–26.
   PubMedGoogle Scholar
• Weintraub D, Chiang C, Kim HM, et al. Association of antipsychotic use with mortality risk in patients with Parkinson disease. JAMA Neurol. 2016;73:535–541.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Chiang C, Kim HM, et al. Antipsychotic use and physical morbidity in Parkinson disease. Am J Geriatr Psychiatry. 2017;25:697–705.
   PubMed Web of Science ®Google Scholar
• Malaty IA, Okun MS, Jaffee M. The danger of not treating Parkinson disease psychosis. JAMA Neurol. 2016;73:1156.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Kales HC, Marras C. The danger of not treating Parkinson disease psychosis-reply. JAMA Neurol. 2016;73:1156–1157.
   PubMed Web of Science ®Google Scholar
• Fox SH, Katzenschlager R, Lim S-Y, et al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2018;33:1248–1266.
   PubMed Web of Science ®Google Scholar
• Commonwealth of Australia. Australian commission on safety and quality in health care: NIMC (clozapine titration) user guide [Internet]. 2012. Available from: www.safetyandquality.gov.au.Access date: 22/11/2020.
   Google Scholar
• Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med. 1999;340:757–763.
   PubMed Web of Science ®Google Scholar
• Merims D, Balas M, Peretz C, et al. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson’s disease psychosis. Clin Neuropharmacol. 2006;29:331–337.
   PubMed Web of Science ®Google Scholar
• Zhang H, Wang L, Fan Y, et al. Atypical antipsychotics for Parkinson’s disease psychosis: a systematic review and meta-analysis. Neuropsychiatr Dis Treat. 2019;15:2137–2149.
   PubMed Web of Science ®Google Scholar
• Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004;75:689–695.
   PubMed Web of Science ®Google Scholar
• Ruggieri S, De Pandis MF, Bonamartini A, et al. Low dose of clozapine in the treatment of dopaminergic psychosis in Parkinson’s disease. Clin Neuropharmacol. 1997;20:204–209.
   PubMed Web of Science ®Google Scholar
• Essali A, Al-Haj Haasan N, Li C, et al. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Re. 2009;2009:CD000059.
   Google Scholar
• Rabey JM, Treves TA, Neufeld MY, et al. Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson’s disease. Neurology. 1995;45:432–434.
   PubMed Web of Science ®Google Scholar
• Zesiewicz TA, Borra S, Hauser RA. Clozapine withdrawal symptoms in a Parkinson’s disease patient. Mov Disord. 2002;17:1365–1367.
   PubMed Web of Science ®Google Scholar
• Keks N, Schwartz D, Hope J. Stopping and switching antipsychotic drugs. Aust Prescr. 2019;42:152–157.
   PubMed Web of Science ®Google Scholar
• Van Leeuwen E, Petrovic M, van Driel ML, et al. Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Re. 2018;3:CD007726.
   PubMedGoogle Scholar
• Fernandez HH, Friedman JH, Jacques C, et al. Quetiapine for the treatment of drug-induced psychosis in Parkinson’s disease. Mov Disord. 1999;14:484–487.
   PubMed Web of Science ®Google Scholar
• Rabey JM, Prokhorov T, Miniovitz A, et al. Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration. Mov Disord. 2007;22:313–318.
   PubMed Web of Science ®Google Scholar
• Shotbolt P, Samuel M, Fox C, et al. A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease. Neuropsychiatr Dis Treat. 2009;5:327–332.
   PubMed Web of Science ®Google Scholar
• Friedman JH. Melperone is ineffective in treating Parkinson’s disease psychosis. Mov Disord. 2012;27:803–804.
   PubMed Web of Science ®Google Scholar
• Breier A, Sutton VK, Feldman PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease. Biol Psychiatry. 2002;52:438–445.
   PubMed Web of Science ®Google Scholar
• Ondo WG, Levy JK, Vuong KD, et al. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord. 2002;17:1031–1035.
   PubMed Web of Science ®Google Scholar
• Goetz CG, Blasucci LM, Leurgans S, et al. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology. 2000;55:789–794.
   PubMed Web of Science ®Google Scholar
• Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383:533–540.
   PubMed Web of Science ®Google Scholar
• Mathis MV, Muoio BM, Andreason P, et al. The US food and drug administration’s perspective on the new antipsychotic pimavanserin. J Clin Psychiatry. 2017;78:e668–e673.
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Mills R, Revell S, et al. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson’s disease psychosis. Neuropsychopharmacology. 2010;35:881–892.
   PubMed Web of Science ®Google Scholar
• Citrome L, Norton JC, Chi-Burris K, et al. Pimavanserin for the treatment of Parkinson’s disease psychosis: number needed to treat, number needed to harm, and likelihood to be helped or harmed. CNS Spectr. 2018;23:228–238.
   PubMed Web of Science ®Google Scholar
• Black KJ, Nasrallah H, Isaacson S, et al. Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson’s disease psychosis: an expert consensus. CNS Spectr. 2018;23:402–413.
   PubMed Web of Science ®Google Scholar
• Horn S, Richardson H, Xie SX, et al. Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson’s disease and dementia with Lewy bodies. Parkinsonism Relat Disord. 2019;69:119–124.
   PubMed Web of Science ®Google Scholar
• Espay AJ, Guskey MT, Norton JC, et al. Pimavanserin for Parkinson’s Disease psychosis: effects stratified by baseline cognition and use of cognitive-enhancing medications. Mov Disord. 2018;33:1769–1776.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA analysis finds no new or unexpected safety risks associated with Nuplazid (pimavanserin), a medication to treat the hallucinations and delusions of Parkinson’s disease psychosis [Internet]; 2018. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-analysis-finds-no-new-or-unexpected-safety-risks-associated-nuplazid-pimavanserin-medication.Access date: 22/11/2020.
   Google Scholar
• Hawkins T, Berman BD. Pimavanserin: a novel therapeutic option for Parkinson disease psychosis. Neurol Clin Pract. 2017;7:157–162.
   PubMedGoogle Scholar
• Swann P, O’Brien JT. Management of visual hallucinations in dementia and Parkinson’s disease. Int Psychogeriatr. 2019;31:815–836.
   PubMed Web of Science ®Google Scholar
• Baumann P. Pharmacology and pharmacokinetics of citalopram and other SSRIs. Int Clin Psychopharmacol. 1996;11(1):5–11.
   PubMedGoogle Scholar
• Sánchez-Soto M, Bonifazi A, Cai NS, et al. Evidence for noncanonical neurotransmitter activation: norepinephrine as a dopamine D2-like receptor agonist. Mol Pharmacol. 2016;89:457–466.
   PubMedGoogle Scholar
• Padala KP, Padala PR, Malloy T, et al. New onset multimodal hallucinations associated with mirtazapine: a case report. Int Psychogeriatr. 2010;22:837–839.
   PubMed Web of Science ®Google Scholar
• Cancelli I, Marcon G, Balestrieri M. Factors associated with complex visual hallucinations during antidepressant treatment. Hum Psychopharmacol. 2004;19:577–584.
   PubMed Web of Science ®Google Scholar
• Bomasang-Layno E, Fadlon I, Murray AN, et al. Antidepressive treatments for Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2015;21:833–842, discussion 833.
   PubMed Web of Science ®Google Scholar
• Bergman J, Lerner PP, Sokolik S, et al. Successful use of escitalopram for the treatment of visual hallucinations in patients with parkinson disease. Clin Neuropharmacol. 2017;40:246–250.
   PubMed Web of Science ®Google Scholar
• Sa DS, Kapur S, Lang AE. Amoxapine shows an antipsychotic effect but worsens motor function in patients with Parkinson’s disease and psychosis. Clin Neuropharmacol. 2001;24:242–244.
   PubMed Web of Science ®Google Scholar
• Voon V, Fox S, Butler TR, et al. Antidepressants and psychosis in Parkinson disease: a case series. Int J Geriatr Psychiatry. 2007;22:601–604.
   PubMed Web of Science ®Google Scholar
• Meco G, Bernardi S. Antidepressant use in treatment of psychosis with comorbid depression in Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:311–313.
   PubMed Web of Science ®Google Scholar
• Ikeguchi K, Kuroda A. Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs. Eur Arch Psychiatry Clin Neurosci. 1995;244:320–324.
   PubMed Web of Science ®Google Scholar
• Godschalx-Dekker JA, Siegers HP. Reduction of parkinsonism and psychosis with mirtazapine: a case report. Pharmacopsychiatry. 2014;47:81–83.
   PubMed Web of Science ®Google Scholar
• Nagata T, Shinagawa S, Tagai K, et al. A case in which mirtazapine reduced auditory hallucinations in a patient with Parkinson disease. Int Psychogeriatr. 2013;25:1199–1201.
   PubMed Web of Science ®Google Scholar
• Sid-Otmane L, Huot P, Panisset M. Effect of antidepressants on psychotic symptoms in Parkinson disease: a review of case reports and case series. Clin Neuropharmacol. 2020;43:61–65.
   PubMed Web of Science ®Google Scholar
• Delucca BJ, Richardson RM, Stewart JT. Melatonin treatment of visual hallucinations in Parkinson disease. J Clin Psychopharmacol. 2018;38:532–534.
   PubMed Web of Science ®Google Scholar
• Borgemeester RWK, Lees AJ, van Laar T. Parkinson’s disease, visual hallucinations and apomorphine: a review of the available evidence. Parkinsonism Relat Disord. 2016;27:35–40.
   PubMed Web of Science ®Google Scholar
• Dafsari HS, Martinez-Martin P, Rizos A, et al. EuroInf 2: subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson’s disease. Mov Disord. 2019;34:353–365.
   PubMed Web of Science ®Google Scholar
• Pessoa RR, Moro A, Munhoz RP, et al. Apomorphine in the treatment of Parkinson’s disease: a review. Arq Neuropsiquiatr. 2018;76:840–848.
   PubMed Web of Science ®Google Scholar
• Geerligs L, Meppelink AM, Brouwer WH, et al. The effects of apomorphine on visual perception in patients with Parkinson disease and visual hallucinations: a pilot study. Clin Neuropharmacol. 2009;32:266–268.
   PubMed Web of Science ®Google Scholar
• Beedham W, Sbai M, Allison I, et al. Cannabinoids in the older person: a literature review. Geriatrics (Basel). 2020;5(1):2.
   Google Scholar
• Stampanoni Bassi M, Sancesario A, Morace R, et al. Cannabinoids in Parkinson’s disease. Cannabis Cannabinoid Res. 2017;2:21–29.
   PubMedGoogle Scholar
• Zuardi AW, Crippa JAS, Hallak JEC, et al. Cannabidiol for the treatment of psychosis in Parkinson’s disease. J Psychopharmacol. 2009;23:979–983.
   PubMed Web of Science ®Google Scholar
• Balash Y, Bar-Lev Schleider L, Korczyn AD, et al. Medical cannabis in parkinson disease: real-life patients’ experience. Clin Neuropharmacol. 2017;40:268–272.
   PubMed Web of Science ®Google Scholar
• Aarsland D, Laake K, Larsen JP, et al. Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry. 2002;72:708–712.
   PubMed Web of Science ®Google Scholar
• Fabbrini G, Barbanti P, Aurilia C, et al. Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease. Neurol Sci. 2002;23:41–43.
   PubMed Web of Science ®Google Scholar
• Kurita A, Ochiai Y, Kono Y, et al. The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson’s disease. J Geriatr Psychiatry Neurol. 2003;16:184–188.
   PubMed Web of Science ®Google Scholar
• Satoh M, Ishikawa H, Meguro K, et al. Improved visual hallucination by donepezil and occipital glucose metabolism in dementia with Lewy bodies: the Osaki-Tajiri project. Eur Neurol. 2010;64:337–344.
   PubMed Web of Science ®Google Scholar
• Sobow T. Parkinson’s disease-related visual hallucinations unresponsive to atypical antipsychotics treated with cholinesterase inhibitors: a case series. Neurol Neurochir Pol. 2007;41:276–279.
   PubMed Web of Science ®Google Scholar
• Klein C, Gordon J, Pollak L, et al. Clozapine in Parkinson’s disease psychosis: 5-year follow-up review. Clin Neuropharmacol. 2003;26:8–11.
   PubMed Web of Science ®Google Scholar
• Jethwa KD, Onalaja OA. Antipsychotics for the management of psychosis in Parkinson’s disease: systematic review and meta-analysis. BJPsych Open. 2015;1:27–33.
   PubMed Web of Science ®Google Scholar
• Ondo WG, Tintner R, Voung KD, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Mov Disord. 2005;20:958–963.
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Okun MS, Rodriguez RL, et al. Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study. Int J Neurosci. 2009;119:2196–2205.
   PubMed Web of Science ®Google Scholar
• Chen JJ, Hua H, Massihi L, et al. Systematic literature review of quetiapine for the treatment of psychosis in patients with Parkinsonism. J Neuropsychiatry Clin Neurosci. 2019;31:188–195.
   PubMed Web of Science ®Google Scholar
• Usui C, Hatta K, Doi N, et al. Improvements in both psychosis and motor signs in Parkinson’s disease, and changes in regional cerebral blood flow after electroconvulsive therapy. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:1704–1708.
   PubMed Web of Science ®Google Scholar
• Nishioka K, Tanaka R, Shimura H, et al. Quantitative evaluation of electroconvulsive therapy for Parkinson’s disease with refractory psychiatric symptoms. J Neural Transm (Vienna). 2014;121:1405–1410.
   PubMed Web of Science ®Google Scholar
• Rektorová I, Anderková Ľ. Noninvasive brain stimulation and implications for nonmotor symptoms in Parkinson’s disease. Int Rev Neurobiol. 2017;134:1091–1110.
   PubMed Web of Science ®Google Scholar
• Brys M, Fox MD, Agarwal S, et al. Multifocal repetitive TMS for motor and mood symptoms of Parkinson disease: a randomized trial. Neurology. 2016;87:1907–1915.
   PubMed Web of Science ®Google Scholar
• Hanoğlu T, Hanoğlu L, Güntekin B, et al. The therapeutic role of repetitive transcranial magnetic stimulation (rTMS) in parkinsonian visual hallucinations: electrophysiological correlates. J Clin Neurosci. 2019;69:281–284.
   PubMed Web of Science ®Google Scholar
• Elder GJ, Colloby SJ, Firbank MJ, et al. Consecutive sessions of transcranial direct current stimulation do not remediate visual hallucinations in Lewy body dementia: a randomised controlled trial. Alzheimers Res Ther. 2019;11:9.
   PubMed Web of Science ®Google Scholar